Aldosterone antagonists in chronic heart failure treatment

Česká verze

Authors: P. Gavornik; Ľ. Gašpar; A. Kunová; I. Gašparová; J. Hodulíková
Authors place of work: II. interná klinika Lekárskej fakulty UK a UN Bratislava, Prvé angiologické pracovisko (PAP) Bratislava, Slovenská republika, prednosta doc. MUDr. Ľudovít Gašpar, CSc.
Published in the journal: Vnitř Lék 2012; 58(7 a 8): 23-28
Category: 80. narozeniny prof. MUDr. Miroslava Mydlíka, DrSc.

Summary

The article provides a review of actual information about the place of aldosterone antagonists in the treatment of chronic heart failure. Arterial hypertension and coronary artery disease are among risk factors/diseases of heart failure. Aldosterone antagonists play an important role in the treatment of NYHA class III and IV chronic heart failure, as shown by the RALES (Randomized Aldactone Evaluation Study) trial in the case of spironolactone. Recent trials have shown spironolactone to significantly improve left ventricular remodeling and left ventricular diastolic function in NYHA class I and II chronic heart failure. Aldosterone antagonists are also effective in treating patients after acute myocardial infarction and heart failure, as demonstrated by the EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) trial for eplerenone. The EMPHASIS-HF mortality trial has documented the efficacy of eplerenone therapy even in a milder stage of chronic heart failure NYHA class II. The effect of eplerenone seems to be a „class“ one as it closely resembles spironolactone action in the more severe forms of heart failure. In clinical practice, it may be appropriate to initiate treatment with spironolactone reserving eplerenone for patients with spironolactone intolerance. This recommendation is due to the different pricing of the two drugs.

Key words:
chronic heart failure – therapy – aldosterone antagonists – spironolactone – eplerenone

Zdroje

1. Leopold JA. Aldosterone, Mineralocorticoid Receptor Activation, and Cardiovascular Remodeling. Circulation 2011; 124: e466–e468.

2. Maron BA, Leopold JA. Aldosterone Receptors Antagonists: Effective but Often Forgotten. Circulation 2010; 121: 934–939.

3. Murín J. Cardiovascular effects of aldosteron. Bratislav Lek Listy 2005; 106: 3–9.

4. Frishman WH, Sica DA (eds). Cardiovascular Pharmacotherapeutics. 3^rd Ed. Minneapolis, Minnesota: Cardiotext Publishing, LLC 2011: 775.

5. Pitt B. Plasma aldosterone levels in patients with coronary artery disease without heart failure or myocardial infarction: implications for pathophysiology, prognosis, and therapy. Eur Heart J 2012; 33: 162–164.

6. Ivanes F, Susen S, Mouquet F et al. Editor‘s choice: Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J 2012; 33: 191–202.

7. Šimko F, Šimko J. Patofyziológia renín-angiotenzín-aldosterónového systému. Cardiol 2002; 11 (Suppl 1): S7–S14.

8. Šimko F, Pechanova O. Recent trends in hypertension treatment: perspectives from animal studies. J Hypertension 2009; 27 (Suppl 6): S1–S60.

9. Šimko F, Pechanova O. Remodelling of the heart and vessels in experimental hypertension: advances in protection. J Hypertension 2010; 28 (Suppl 1): S1–S62.

10. Horký K. Aldosteron jako endogenní kardiovaskulární toxin a možnosti jeho terapeutického ovlivnění. Vnitř Lék 2011; 57: 1012–1016.

11. Špinar J, Vítovec J, Špinarová L. Farmakoterapie chronického srdečního selhání po prvních 10 letech 21. století. Vnitř Lék 2011; 57: 959–965.

12. Špinarová L, Špinar J, Vítovec J. Farmakoterapie po srdečním infarktu. Vnitř Lék 2011; 57: 966–969.

13. Gavorník P. Etiopatogenéza a diferenciálna diagnóza edémových stavov. Cardiology 2009; 18: 73–78.

14. Horký K. Je aldosteron endogenním kardiovaskulárním toxinem? Cor Vasa 2011; 53: 578–579.

15. Jerie P. Antagonisté aldosteronu/diuretika šetřící kalium. Renesance staré léčby srdeční insuficiencie – eplerenon. Cor Vasa 2011; 53: 579–582.

16. Uhliar R, Gajdoš M, Štrbová J. Miesto antagonistov aldosterónu v liečbe chronického srdcového zlyhania. Interná Med 2006; 6: 489–494.

17. Vítovec J, Špinarová L. Srdeční glykosidy a diuretika v léčbě srdečního selhání. Kardiol Prax 2006; 4: 20–22.

18. Kisaka T, Ozono R, Nishioka K et al. Elevated plasma aldosteron to renin ratio is associated with future cardiovascular events in Japanese patients with essential hypertension. Available at: http://escardio.org/congresses/esc2011-final-programme-w.P5261.

19. Dickstein K, Cohen-Solal A, Fillippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388–2442.

20. Jessup M, Abraham WT, Casey DE et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. 2009 Writing group to review new evidence and update the 2005 guideline for the management of patients with chronic heart failure writing on behalf of the 2005 heart failure writing committee. Circulation 2009; 119: 1977–2016.

21. Schocken DD, Benjamin EJ, Fonarow GC et al. Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008; 117: 2544–2565.

22. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J 2011; 32: 2739–2747.

23. Armstrong PW. Aldosterone antagonists –last man standing? N Engl J Med 2011; 364: 79–80.

24. Pitt B, Zannad F, Remme WJ et al. Randomized Aldactone Evaluation Study (RALES) Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717.

25. Vizzardi E, D’Aloia A, Giubbini R et al. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. J Am Cardiol 2010; 106: 1292–1296.

26. Brown NJ. Eplerenon: Cardiovascular Protection. Circulation 2003; 107: 2512–2518.

27. Černušková L. Eplerenón. Farm Obzor 2005; 74: 277–299.

28. Pitt B, Remme W, Zannad F et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (EPHESUS). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321.

29. Iraqi W, Rossignol P, Angioi M et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009; 119: 2471–2479.

30. Rossignol P, Ménard J, Fay R et al. Eplerenone Survival Benefits in Heart Failure Patients Post-Myocardial Infarction Are Independent From its Diuretic and Potassium-Sparing Effects: Insights From an EPHESUS (Eplerenone Post--Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) Substudy. J Am Coll Cardiol 2011; 58: 1958–1966.

31. Zannad F, McMurray JV, Krum H et al for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11–21.

32. Pitt B. PEARL-HF: A Multicentre, Randomized, Double-blind, Placebo-Controlled, Parallel Group Multiple Dose Study To Evaluate the Effects of RLY5016 in Heart Failure. New potassium-binding resin reduced hyperkalemia in heart failure. Available at: http://www.theheart.org/article/1114035.do.

33. Widimský J. Antagonisté aldosteronových receptorů v léčbě chronického srdečního selhání. Výsledky nové studie EMPHASIS-HF. Cor Vasa 2011; 53: 112–117.

34. Špinar J, Vítovec J, Špinarová L. FARIM – FARmakoterapie po Infarktu Myokardu. Vnitř Lék 2011; 57: 778–784.

35. Gavorník P. Obliterujúce choroby artérií a končatinovocievna ischemická choroba. Nová klinicko-etiologicko-anatomicko-patofyziologická (CEAP) klasifikácia. Cardiology 2010; 19: 201–213.

36. Gavorník P. Končatinovocievne ischemické choroby. B 2.1: 1–92. In: Gavorník P, Hrubiško M, Rozborilová E (eds). Diferenciálna diagnostika kardio-vaskulárnych, respiračných a hematologických ochorení. Bratislava: Dr. Josef Raabe 2010: 300.

37. Smith SC Jr., Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. A Guideline From the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol 2011; 58(23): 2432–2446.

38. Rydén L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88–136.

39. Ryšavá R. Proteinurie v ambulantní praxi. Vnitř Lék 2011; 57: 747–750.

40. Mancia G, De Backer G, Dominiczak H et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–1187.

41. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–2158.

42. Sever PS, Messerli FH. Hypertension management 2011: Optimal combination therapy. Eur Heart J 2011; 32: 2499–2506.

43. Aronow WS, Fleg JL, Pepine CJ et al. ACCF//AHA 2011 Expert Consensus Document on Hypertension in the Erderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011; 123: 2434–2506.

44. Calhoun DA, Jones D, Textor S et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510–e526.

45. Gavorník P, Dukát A, Gašpar Ľ et al. Odporúčania Sekcie angiológov SLK pre manažment artériovej hypertenzie (2011). Cievy – páchateľky, nástroje i obete artériovej hypertenzie (cievnej choroby cievnych chorôb). Ateroskleróza 2011; 15: 79–84.

46. Gavorník P, Gašpar Ľ, Dukát A et al. Fibrilácia predsiení – následok i príčina artériových orgánovovaskulárnych chorÔb. Odporúčania manažmentu podľa Sekcie angiológov SLK (2011). Ateroskleróza 2011; 13: 161–164.

47. Camm AJ, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Developed with special contribution of the European Heart Rhythm Association (EHRA) and Endorsed by The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2369–2429.